Results from the Phase 3 STRIDE-13 trial presented at the 6th ESCMID Conference on Vaccines
Merck to share STRIDE-13 results with global regulatory authorities
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) at the 6th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conference on Vaccines, taking place in Lisbon, Portugal. The trial evaluated the safety, tolerability and immunogenicity of CAPVAXIVE compared to PPSV23 (pneumococcal 23-valent polysaccharide vaccine) in children and adolescents aged 2 to <18 years who have completed a primary pediatric pneumococcal vaccination regimen and have one or more chronic medical conditions that put them at an increased risk of pneumococcal disease.
Key findings from the STRIDE-13 study include:
- CAPVAXIVE elicited immune responses to all 21 serotypes (or strains) as assessed by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 30 days post-vaccination (secondary immunogenicity endpoint);
- CAPVAXIVE was noninferior to PPSV23 for each of the 12 serotypes shared between the vaccines and superior to PPSV23 for each of the nine serotypes unique to CAPVAXIVE, as measured by serotype-specific OPA GMTs at 30 days post-vaccination (primary immunogenicity endpoint);
- The proportions of participants with adverse events (AEs), including systemic and serious vaccine-related AEs, were generally comparable between groups (primary safety endpoint).
These results will be presented today (Abstract #00093) at the 6th Vaccines Conference organized by the ESCMID, in scientific collaboration with the European Society for Paediatric Infectious Diseases (ESPID), the European Association of Hospital Pharmacists (EAHP) and the European Medicines Agency (EMA).
“Children and adolescents living with chronic medical conditions are at increased risk of pneumococcal disease and offering them additional protection is essential,” said Dr. Rotem Lapidot, chief of Pediatric Infectious Diseases at Rambam Health Care Campus and investigator, STRIDE-13 trial. “Results from STRIDE-13 demonstrate the potential of CAPVAXIVE to deliver protection for these vulnerable populations, who may benefit from additional pneumococcal disease coverage by including serotypes not contained in other approved pneumococcal infant regimens.”
CAPVAXIVE is indicated in the U.S. for:
- Active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B in individuals 18 years of age and older;
- Active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B in individuals 18 years of age and older.
CAPVAXIVE should not be administered to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid; see additional Select Safety Information below.
The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B is approved under accelerated approval based on immune responses as measured by OPA. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
“While CAPVAXIVE was designed to specifically cover the serotypes that cause the majority of invasive pneumococcal disease (IPD) cases in adults, findings from STRIDE-13 underscore its added potential to help protect children and adolescents who are at an increased risk,” said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines, Global Clinical Development, Merck Research Laboratories. “We are encouraged by the safety and immunogenicity data presented at the 6th ESCMID Conference on Vaccines, which underpin our commitment to ensuring infants and adults have access to protection against invasive pneumococcal disease.”
CAPVAXIVE is specifically designed for adults and helps provide coverage against the serotypes responsible for approximately 84% of IPD cases in adults 50 years of age and older, compared to approximately 52% covered by PCV20 (pneumococcal 20-valent conjugate vaccine), based on national-level CDC data from 2018-2022. In children and adolescents ages 2 to <18 years of age who are at increased risk of IPD, CAPVAXIVE has the potential to provide additional protection by covering approximately 78% of IPD cases, with 11 unique serotypes that account for approximately 34% of IPD cases, based on national-level CDC data from 2019-2023 in individuals 2-17 years old.
These values do not reflect the efficacy of the respective vaccines. There are currently no studies comparing the efficacy of CAPVAXIVE and PCV20.
These results from STRIDE-13 represent the final readout of the Phase 3 STRIDE clinical program and will be shared with global regulatory authorities. CAPVAXIVE is currently approved in the U.S., European Union, Japan and multiple other countries around the world, based on safety and immunogenicity data from the Phase 3 STRIDE clinical program.
STRIDE-13 Data (Abstract #00093)
STRIDE-13 (NCT06177912) is a Phase 3, randomized, double-blind, active comparator-controlled clinical study, evaluating the immunogenicity, safety and tolerability of CAPVAXIVE compared to PPSV23 in children and adolescents aged ≥2 to <18 years with increased risk for pneumococcal disease due to medical conditions (including diabetes mellitus, chronic compensated liver disease, chronic lung disease, chronic heart disease or chronic kidney disease). The study enrolled 882 participants who were randomized 3:2 to receive a single dose of CAPVAXIVE or PPSV23, following completion of a primary pediatric pneumococcal vaccine regimen, including PCV7 (pneumococcal 7-valent conjugate vaccine), PCV10 (pneumococcal 10-valent conjugate vaccine) or PCV13 (pneumococcal 13-valent conjugate vaccine).
Immunogenicity of CAPVAXIVE serotypes was assessed 30 days post-vaccination by measuring serotype-specific OPA GMTs. Safety was evaluated as the proportion of participants with AEs. Results demonstrated that:
- CAPVAXIVE was immunogenic for all 21 serotypes as assessed by serotype-specific OPA GMTs at 30 days post-vaccination;
- Immune responses elicited by CAPVAXIVE were noninferior to PPSV23 for each of the 12 serotypes shared between the vaccines (lower bound of the two-sided 95% confidence interval for the serotype-specific OPA GMT ratio >0.5), as measured by the pre-specific statistical criteria;
- CAPVAXIVE demonstrated superiority to PPSV23 for each of the nine serotypes included in CAPVAXIVE but not PPSV23 (lower bound of the two-sided 95% confidence interval for the serotype-specific OPA GMT ratio >2.0), as measured by serotype-specific OPA GMTs at 30 days post-vaccination;
- The proportions of participants with solicited systemic AEs and serious vaccine-related AEs were generally comparable between groups, and solicited injection-site AEs were higher in the CAPVAXIVE group (72.3%) compared to the PPSV23 group (58.2%).
